Crossmark

Pharmacokinetic comparison of ezetimibe/rosuvastatin/telmisartan 10/20/80 mg fixed-dose combination versus coadministration of separate tablets in healthy participants

Crossref DOI link: https://doi.org/10.1007/s00210-025-04903-4

Published Online: 2026-01-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Goh, Seoyoung

Huh, Ki Young

Lee, SeungHwan

Cho, Joo-Youn

Yu, Kyung-Sang
Funding

Funding for this research was provided by:

Seoul National University
License Information

Text and Data Mining valid from 2026-01-08

Version of Record valid from 2026-01-08
More Information

Article History

Received: 8 July 2025

Accepted: 8 December 2025

First Online: 8 January 2026

Declarations

:

: This study protocol was reviewed and approved by the Korean Ministry of Food and Drug Safety and the Institutional Review Board of H Plus Yangji Hospital (Seoul, Republic of Korea). The study was registered with the Clinical Research Information Service in Korea (date 2024.05.02; no. KCT0009387). Informed consent was obtained from all individual participants included in the study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below